A new approach to metastatic melanoma discovered

(IMIM (Hospital del Mar Medical Research Institute)) Combining chemotherapy with a BRAF oncogene inhibitor proves effective at treating this disease. The study, published in the journal Oncogene, was led by researchers from the Hospital del Mar Medical Research Institute, Hospital del Mar and CIBERONC. This alternative paves the way towards a new approach for patients affected by this type of tumour, which has no cure in the most advanced stages or cases of relapse.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Spanholtz Adoptive cell therapy (ACT) represents a promising alternative approach for patients with treatment-resistant metastatic melanoma. Lately, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR)-T cell therapy have shown improved clinical outcome, compared to conventional chemotherapy or immunotherapy. Nevertheless, they are limited by immune escape of the tumor, cytokine release syndrome, and manufacturing challenges of autologous therapies. Conversely, the clinical use of Natural Killer (NK) cells has demonstrated a favorable clinical safety profile with minimal toxicities, providing...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039952. doi: 10.1177/15330338211039952.ABSTRACTCholangiocarcinoma is a general term for intrahepatic and extrahepatic malignant tumors deriving in the biliary system. According to the location, it is divided into intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and distal cholangiocarcinoma. Progressive cholangiocarcinoma yields poor outcomes with radiotherapy; therefore, there is an urgent need for new therapeutic breakthroughs. Immune checkpoint inhibitor (ICI) therapy brings the treatment for cancer into a new field, with the use of drugs targeting PD-1/PD-L...
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Source Type: research
Cancers, Vol. 13, Pages 4620: Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures Cancers doi: 10.3390/cancers13184620 Authors: Christel Larbouret Laurent Gros André Pèlegrin Thierry Chardès Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo-combinations) or to different targets (hetero-combinations) ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Br J Dermatol. 2021 Sep 12. doi: 10.1111/bjd.20758. Online ahead of print.ABSTRACTImmuno-oncology (IO) drugs are an essential treatment option for BRAF wild-type melanoma. However, effective treatment for IO drug-resistant BRAF wild-type melanoma is yet to be established. The proportion of BRAF wild-type melanoma is known to be higher in acral lentiginous melanoma (ALM) and mucosal melanoma (MCM) than in other clinical subtypes.1 Consequently, treatment options other than IO drugs have important implications for these clinical subtypes. Several studies have reported that the response rate (RR) of chemotherapy increases aft...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Source Type: research
In conclusion, this study demonstrates that [Ru(bpy)2BC]Cl2 is a multi-mechanistic PACT drug which exhibits promising anticancer potential.PMID:34508709 | DOI:10.1016/j.cbi.2021.109644
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Source Type: research
Tidsskr Nor Laegeforen. 2021 Aug 19;141(2021-12). doi: 10.4045/tidsskr.21.0194. Print 2021 Sep 7.ABSTRACTFor locally advanced soft tissue sarcomas and metastases from melanoma located in the extremities, mutilating surgery or amputation may be necessary to achieve local control. Isolated limb perfusion with high-dose chemotherapy may represent an alternative to amputation for this patient group.PMID:34505491 | DOI:10.4045/tidsskr.21.0194
Source: Tidsskrift for den Norske Laegeforening - Category: General Medicine Authors: Source Type: research
Acral melanomas are a unique subset of melanomas occurring on the palms, soles, and nails. There is poor prognosis with surgery alone and no specific guidelines for the treatment of metastatic acral melanoma. This meta-analysis explored the systemic therapy outcomes for metastatic acral melanoma. Medline, Pubmed, EMBASE, and the grey literature were searched from 2010 to August 2020 for studies specifying the treatment outcome of metastatic acral melanoma. Studies were assessed by two investigators. A random-effects meta-analysis was performed and pooled Kaplan–Meier curves for progression-free survival and overall s...
Source: Melanoma Research - Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research
The objective of this study was to explore the chemotherapy-sensitizing effect of celecoxib on TMZ in GBM cells and its potential mechanisms. From the study, we found that the combination therapy (TMZ 250uM+celecoxib 30uM) showed excellent inhibitory effect to the GBM, the LN229 and LN18, which were the TMZ resistant GBM cell lines. Our data suggest that the combination therapy may inhibits cell proliferation, increases apoptosis, and increases the autophagy on LN229 and LN18. The potential molecular mechanisms were related to mitochondrial metabolism and respiratory chain inhibition.PMID:34497154 | DOI:10.18632/aging.203443
Source: Aging - Category: Biomedical Science Authors: Source Type: research
Eva Lion Despite the advent of novel therapies, acute myeloid leukemia (AML) remains associated with a grim prognosis. This is exemplified by 5-year overall survival rates not exceeding 30%. Even with frontline high-intensity chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the majority of patients with AML will relapse. For these patients, treatment options are few, and novel therapies are urgently needed. Adoptive T-cell therapies represent an attractive therapeutic avenue due to the intrinsic ability of T lymphocytes to recognize tumor cells with high specificity and efficiency. In par...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
BackgroundTreatment of malignant melanoma has undergone a paradigm shift with the advent of immune checkpoint inhibitors (ICI) and targeted therapies. However, access to ICI is limited in low-middle income countries (LMICs).Patients and MethodsHistologically confirmed malignant melanoma cases registered from 2013 to 2019 were analysed for pattern of care, safety, and efficacy of systemic therapies (ST).ResultsThere were 659 patients with a median age of 53 (range 44–63) years; 58.9% were males; 55.2% were mucosal melanomas. Most common primary sites were extremities (36.6%) and anorectum (31.4%). Nearly 10.8% of the ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hospitals | International Medicine & Public Health | Melanoma | Research | Skin Cancer | Study